Best ETF Areas of Last Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2024
0mins
Source: NASDAQ.COM
Wall Street Performance:
- S&P 500, Dow Jones, and Nasdaq Composite all saw gains last week due to easing inflation, soft manufacturing data, and a tech rally.
- Treasury yields declined, boosting the market rally, with technology stocks seeing significant inflows.
US Economy:
- The US economy added 272,000 jobs in May 2024, the highest in five months, surpassing forecasts and previous monthly gains.
Winning ETF Areas:
- Bitcoin Miners ETFs surged, reflecting confidence in potential Fed rate cuts.
- Natural Gas ETFs rose as natural gas maintains a critical role in U.S. electricity generation.
- Semiconductor ETFs performed well, driven by NVIDIA's growth in AI chips for data centers.
Weight-Loss Drugs:
- Weight loss drug manufacturers' shares increased, with expectations of a growing market due to rising obesity rates.
- Intense competition exists among companies producing GLP-1 medicines, seen as revolutionary in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 40.810
Low
42.00
Averages
54.67
High
70.00
Current: 40.810
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Foundayo Prescriptions Surge Post Launch
- Prescription Surge: Eli Lilly's new weight loss pill, Foundayo, saw prescriptions reach 1,390 for the week ending April 10, indicating a strong market response since its launch earlier this month, reflecting consumer acceptance of the new therapy.
- Competitor Performance: In contrast, Novo Nordisk's Wegovy approached 113,354 prescriptions during the same week, up from 105,366 the previous week, highlighting the sustained demand for GLP-1 drugs and intensifying competition in the market.
- FDA Approval Impact: Foundayo received FDA approval on April 1 as a once-daily treatment for obese or overweight adults, quickly accepting prescriptions through LillyDirect, showcasing the company's rapid market response capabilities.
- Market Outlook: With the launch of Foundayo, Eli Lilly significantly enhances its competitive position in the GLP-1 market, expected to challenge Novo Nordisk's market share and drive further growth in the overall weight loss drug market.
See More
Viking Therapeutics: A Potential Obesity Market Leader
- Surging Market Demand: The obesity treatment sector is experiencing explosive demand, with projections suggesting a market size nearing $100 billion by the decade's end, positioning Viking Therapeutics as a potential beneficiary of significant revenue opportunities.
- Clinical Trial Progress: Viking's VK2735 injectable is currently in phase 3 trials, having completed enrollment ahead of schedule, indicating strong patient interest; successful trial outcomes could pave the way for commercialization and revenue generation.
- Competitive Edge: As a GLP-1 class drug, Viking's candidate could provide a competitive alternative to existing products from Lilly and Novo, potentially capturing market share and generating substantial income if it successfully enters the market.
- Investment Return Potential: Although Viking has yet to achieve profitability, its stock surged 121% on positive phase 2 news, highlighting its volatility; continued positive developments could yield significant returns for investors in the future.
See More
Viking Therapeutics Targets Billion-Dollar Obesity Market
- Clinical Trial Progress: Viking Therapeutics' VK2735 injectable is currently in a phase 3 trial that completed enrollment ahead of schedule, indicating strong market demand for this potential new drug, which could secure a foothold in the obesity drug market if successful.
- Massive Market Potential: The obesity drug market is projected to approach $100 billion by 2030, and if Viking's products are successfully commercialized, the company could capture a significant share of this lucrative market, driving substantial growth.
- Competitive Landscape Analysis: With Eli Lilly and Novo Nordisk currently dominating the market, Viking's promising clinical candidates could generate considerable revenue if they reach commercialization, thereby enhancing the company's competitive position.
- Investor Attention: Although Viking's stock surged 121% in early 2024 due to positive news, caution is warranted as investors should closely monitor the ongoing developments in its obesity program to assess long-term investment potential.
See More
Novo Nordisk Plans to Add 2,000 Employees Amid Restructuring
- Hiring Initiative: Novo Nordisk plans to add approximately 2,000 employees in 2025, with 1,400 already onboard, including nearly 400 in Denmark, despite facing a 5% voluntary attrition rate and an overall turnover rate nearing 18%.
- Restructuring Context: Under new CEO Mike Doustdar, the company underwent significant restructuring in 2025, cutting about 7,800 roles, or 10% of its workforce, indicating deep changes even at senior levels.
- Recruitment vs. Attrition: This hiring push is more about filling gaps created by layoffs rather than team expansion, highlighting the challenges and opportunities the company faces in its recovery process.
- Future Outlook: While the hiring initiative appears positive, the company must still tackle the challenges posed by high turnover rates to ensure that new hires can effectively integrate into the team and drive sustained growth.
See More
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
Eli Lilly's Foundayo Prescriptions Surge Post Launch
- Prescription Surge: Eli Lilly's new weight loss pill, Foundayo, saw prescriptions reach 1,390 for the week ending April 10, indicating a strong market response since its launch earlier this month, reflecting consumer acceptance of the new therapy.
- Competitor Performance: In contrast, Novo Nordisk's Wegovy approached 113,354 prescriptions during the same week, up from 105,366 the previous week, highlighting the sustained demand for GLP-1 drugs and intensifying competition in the market.
- FDA Approval Impact: Foundayo received FDA approval on April 1 as a once-daily treatment for obese or overweight adults, quickly accepting prescriptions through LillyDirect, showcasing the company's rapid market response capabilities.
- Market Outlook: With the launch of Foundayo, Eli Lilly significantly enhances its competitive position in the GLP-1 market, expected to challenge Novo Nordisk's market share and drive further growth in the overall weight loss drug market.
See More
Viking Therapeutics: A Potential Obesity Market Leader
- Surging Market Demand: The obesity treatment sector is experiencing explosive demand, with projections suggesting a market size nearing $100 billion by the decade's end, positioning Viking Therapeutics as a potential beneficiary of significant revenue opportunities.
- Clinical Trial Progress: Viking's VK2735 injectable is currently in phase 3 trials, having completed enrollment ahead of schedule, indicating strong patient interest; successful trial outcomes could pave the way for commercialization and revenue generation.
- Competitive Edge: As a GLP-1 class drug, Viking's candidate could provide a competitive alternative to existing products from Lilly and Novo, potentially capturing market share and generating substantial income if it successfully enters the market.
- Investment Return Potential: Although Viking has yet to achieve profitability, its stock surged 121% on positive phase 2 news, highlighting its volatility; continued positive developments could yield significant returns for investors in the future.
See More
Viking Therapeutics Targets Billion-Dollar Obesity Market
- Clinical Trial Progress: Viking Therapeutics' VK2735 injectable is currently in a phase 3 trial that completed enrollment ahead of schedule, indicating strong market demand for this potential new drug, which could secure a foothold in the obesity drug market if successful.
- Massive Market Potential: The obesity drug market is projected to approach $100 billion by 2030, and if Viking's products are successfully commercialized, the company could capture a significant share of this lucrative market, driving substantial growth.
- Competitive Landscape Analysis: With Eli Lilly and Novo Nordisk currently dominating the market, Viking's promising clinical candidates could generate considerable revenue if they reach commercialization, thereby enhancing the company's competitive position.
- Investor Attention: Although Viking's stock surged 121% in early 2024 due to positive news, caution is warranted as investors should closely monitor the ongoing developments in its obesity program to assess long-term investment potential.
See More
Novo Nordisk Plans to Add 2,000 Employees Amid Restructuring
- Hiring Initiative: Novo Nordisk plans to add approximately 2,000 employees in 2025, with 1,400 already onboard, including nearly 400 in Denmark, despite facing a 5% voluntary attrition rate and an overall turnover rate nearing 18%.
- Restructuring Context: Under new CEO Mike Doustdar, the company underwent significant restructuring in 2025, cutting about 7,800 roles, or 10% of its workforce, indicating deep changes even at senior levels.
- Recruitment vs. Attrition: This hiring push is more about filling gaps created by layoffs rather than team expansion, highlighting the challenges and opportunities the company faces in its recovery process.
- Future Outlook: While the hiring initiative appears positive, the company must still tackle the challenges posed by high turnover rates to ensure that new hires can effectively integrate into the team and drive sustained growth.
See More
CNBC Investing Club April Meeting Highlights
- Market Rebound Analysis: The S&P 500 index reached a record high in April, marking a significant recovery from the Iran war sell-off, indicating a renewed focus on company fundamentals despite the ongoing conflict, which underscores the importance of investor calmness.
- Nike Investment Reflection: Despite insider buying signals prompting us to increase our stake in Nike last December, we are now skeptical about CEO Elliott Hill's ability to turn the company around, and if next quarter's performance is disappointing, we will consider exiting.
- Amazon Cloud Business Recovery: Amazon's stock rebound highlights the importance of patience, as the market is gradually recognizing the strength of its AWS cloud division and online retail business, which are expected to continue growing in the future.
- Nvidia Market Leadership: Nvidia's leading position in the AI chip sector is paying off, and despite competitive pressures, its advantage in computing power positions it well to maintain market leadership going forward.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
